Share-based Payment Arrangement, Expense of Elicio Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Elicio Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Elicio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $698,000, a 122% increase year-over-year.
  • Elicio Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,389,000, a 80% increase year-over-year.
  • Elicio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,452,000, a 23% increase from 2023.
  • Elicio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,179,000, a 104% increase from 2022.
  • Elicio Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $579,000, a 95% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Elicio Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,389,000 $698,000 +$384,000 +122% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $2,005,000 $710,000 +$360,000 +103% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $1,645,000 $517,000 +$193,000 +60% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $1,452,000 $464,000 +$127,000 +38% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $1,325,000 $314,000 -$25,000 -7.4% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,350,000 $350,000 +$71,000 +25% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $1,279,000 $324,000 +$100,000 +45% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $1,179,000 $337,000 +$12,000 +3.7% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $1,167,000 $339,000 +$229,000 +208% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $938,000 $279,000 +$166,000 +147% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $772,000 $224,000 +$193,000 +623% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $579,000 $325,000 -$1,697,000 -84% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $2,276,000 $110,000 -$2,074,000 -95% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $4,350,000 $113,000 -$2,605,000 -96% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,955,000 $31,000 -$5,086,000 -99% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $12,041,000 $2,022,000 +$860,000 +74% 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
Q3 2021 $11,181,000 $2,184,000 +$557,000 +34% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $10,624,000 $2,718,000 +$1,623,000 +148% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $9,001,000 $5,117,000 +$4,285,000 +515% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $4,716,000 $1,162,000 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022 2021 FY
Q3 2020 $1,627,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $1,095,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $832,000 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1

Elicio Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,452,000 +$273,000 +23% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $1,179,000 +$600,000 +104% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $579,000 -$11,462,000 -95% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $12,041,000 +$7,325,000 +155% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
2020 $4,716,000 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.